Share on StockTwits

Ambit Biosciences Corp (NASDAQ:AMBI) posted its quarterly earnings results on Wednesday. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.58) by $0.10, AnalystRatings.NET reports.

On the ratings front, analysts at TheStreet initiated coverage on shares of Ambit Biosciences Corp in a research note on Wednesday, June 18th. They set a “sell” rating on the stock.

Shares of Ambit Biosciences Corp (NASDAQ:AMBI) opened at 5.78 on Wednesday. Ambit Biosciences Corp has a 52-week low of $4.80 and a 52-week high of $21.44. The stock’s 50-day moving average is $5.88 and its 200-day moving average is $7.83. The company’s market cap is $103.9 million.

Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.